Tempest Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 17
- Market Cap
- $33.7M
- Website
- http://www.tempesttx.com
- Introduction
Tempest Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company was founded in 2011 and is headquartered in Brisbane, CA.
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tempest Therapeutics granted two employees nonqualified stock options for 79,500 shares, vesting over four years.
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
Tempest Therapeutics announces positive FDA feedback for amezalpat (TPST-1120) in treating first-line hepatocellular carcinoma, with agreement on Phase 3 study design and endpoints.
© Copyright 2024. All Rights Reserved by MedPath